Selskabsmeddelelse25.6.2025, 15.00Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025
Selskabsmeddelelse25.6.2025, 12.00Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market
Selskabsmeddelelse26.2.2025, 17.40Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks
Selskabsmeddelelse26.2.2025, 17.35Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report
Selskabsmeddelelse26.2.2025, 17.30Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting
Selskabsmeddelelse13.1.2025, 06.00Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer
Selskabsmeddelelse20.11.2024, 16.30Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million
Selskabsmeddelelse14.11.2024, 07.30Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024
Pressemeddelelse5.11.2024, 16.00Invitation to Scandion Oncology webcast and conference call November 11, 2024
Selskabsmeddelelse4.11.2024, 07.30Scandion Oncology announces the start of the exercise period for warrants of series TO 2
Selskabsmeddelelse31.10.2024, 07.30Correction: Scandion Oncology announces exercise price for warrants of series TO 2
Selskabsmeddelelse30.10.2024, 16.00Scandion Oncology announces exercise price for warrants of series TO 2